Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie

Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former...

      

Related Stories

• Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant
• Lupin Upbeat On Biosimilar Etanercept After Q3 Profit Plunge
• Small Study Offers Hope For PARP/PD-L1 Combos In Prostate Cancer

 

Original Article: Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie

More From BioPortfolio on "Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie"